TickerTalks
Browse all tickers →
TickerTalks›$QURE
QUQURE

uniQure N.V.

$QURE·$1.6B·Biotechnology·Healthcare
$22.14-1.7%YTD-11.4%1Y-64.2%
Price updated 8m ago·X counts updated 5d ago
QUQURE
$QUREuniQure N.V.
$22.14-1.69%194 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $QURE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

194X posts · last 7 days
Sep 28Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $QURE's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data16 posts analyzed · as of 2026-10-02

Sentiment is defensively bullish into Wednesday's AMT-130 four-year Huntington's readout — longs cite a 75% slower progression vs matched external control from the three-year data and FDA special designations QURE and NVS have but Skyhawk doesn't. The thread's drama is a short-seller framing campaign tied to Dr. Sarah Tabrizi's unflagged consulting conflict and her downbeat posture ahead of print. Longs reading this as a classic data-run psyop.

Read what X is saying about $QURE

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $QURE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventSelling offAI verdict · as of 2026-10-03

Falling on heavy selling — points lower unless it turns around.

Gene-therapy biotech with a Huntington's BLA filed — but Sep 30 data update already broke the setup and the short-seller campaign is live.

uniQure is a gene-therapy biotech with HEMGENIX (hemophilia B) and AMT-130 (Huntington's) — the pivotal data readouts drive the stock. A Sep 30 four-year Huntington's data update broke the recent setup and the stock is now sitting on a 57% TTM decline with a BLA in with the FDA.

  • The business is pre-commercial scale: Q1 2026 revenue of $3.6M against a $2.65B market cap — this is a bet on AMT-130 approval and HEMGENIX commercial ramp, with 2028 consensus revenue of $365M.
  • AMT-130 is still in flight: BLA for Huntington's gene therapy submitted Sep 2 seeking accelerated approval — the ongoing PDUFA process is the stock's near-term catalyst, but the Sep 30 data update plunge is the live counter-signal.
  • The short-seller campaign is active: the Kirby McInerney securities investigation plus a short-seller framing campaign tied to Dr. Sarah Tabrizi's unflagged consulting conflicts — the risk here is more legal and perception than clinical.

An FDA PDUFA acceptance of the BLA by year-end re-rates the stock sharply; a Complete Response Letter or further Huntington's safety concerns and the breakdown accelerates toward the 52-week lows.

Agrees with X sentimentX is defensively bullish into the AMT-130 four-year data readout citing 75% slower progression and FDA special designations — both real signals. The crowd correctly identifies the short-seller framing as a Tabrizi consulting-conflict psyop, but the Sep 30 plunge on "additional data" is a legitimate counter the bulls still have to answer.

What to watch: FDA PDUFA acceptance of the AMT-130 BLA (filed Sep 2) and any further Huntington's data readouts. Nov 9 Q3 earnings — cash runway and any dilutive follow-on. A PDUFA acceptance restarts the setup; a Complete Response Letter or additional safety signal and the breakdown accelerates.

On the calendar: 2026-11-09 — Q3 2026 earnings

Read the AI verdict on $QURE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Gene therapy company with hemophilia B therapy (etranacogene) in pivotal trials and AMT-130 for Huntington's disease.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $QURE.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $QURE

Neutral — Gene therapy company with hemophilia B therapy (etranacogene) in pivotal trials and AMT-130 for Huntington's disease.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-14.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-26.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
167.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-146%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
74.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$-1.22$-0.82-48.4%
Q1 2026May 5, 2026$-0.85$-0.88+3.4%
Q4 2025Mar 2, 2026$-0.56$-0.93+39.8%
Q3 2025Nov 10, 2025$-1.38$-0.85-62.4%
Next earningsMon, Nov 9·consensus EPS $-0.92

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.6M+127.3%93.9%-1243%$-0.85$-38.4M
Q4 FY25$5.6M+6.6%38.8%-937%$-0.59$-77.2M
Q3 FY25$3.7M+61.8%89.2%-1379%$-1.38$-16.3M
Q2 FY25$5.3M-52.7%87.5%-834%$-0.69$-40.2M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$22.3M$17.6M – $28.4M-$3.89-$4.14 – -$3.698
FY27$115.5M$104.7M – $126.2M-$3.03-$3.32 – -$2.667
FY28$365.6M$89.9M – $735.7M-$0.79-$2.83 – $2.087
FY29$554.8M$177.9M – $1.2B$1.05$0.12 – $2.603
FY30$841.9M$269.9M – $1.8B$3.65$0.43 – $9.075

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.22%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-43.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-24.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 57.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.945-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Matthew C KapustaCEO21.1K sh$952KSellJun 30Jack KayeDirector21.2K sh$983KSellJun 30Walid Abi-saabChief Medical Officer30.0K sh$1.4MSellJun 26Walid Abi-saabChief Medical Officer1.4K sh$67KSellJun 25Matthew C KapustaCEO28.7K sh$1.4MSellJun 24Matthew C KapustaCEO6.7K sh$335KSellJun 18Matthew C KapustaCEO41.7K sh$2.1MSellJun 17Jack KayeDirector5.3K sh$225KSellJun 17Madhavan BalachandranDirector11.7K sh$526KSellJun 17Matthew C KapustaCEO164.4K sh$7.3M
1–10 of 23
+ 20 other (13 exempts · 7 awards) in window

See when $QURE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 298-K — Item 7.01: Press release / Reg FD
AI summary

uniQure N.V. (QURE) filed a Regulation FD disclosure (8-K Item 7.01) on 2026-09-29. The excerpt shows only the cover page; the actual disclosed material (typically investor presentation slides, a press release, or conference call transcript) is attached as an exhibit. Reg FD events can contain forward-looking statements or updated guidance material to investors.

8-KPress release / Reg FDSep 28-K — Item 7.01: Press release / Reg FD
AI summary

uniQure (QURE) filed an 8-K (Item 8.01) announcing submission of a Biologics License Application (BLA) to the FDA for AMT-130, its gene therapy for Huntington's disease, seeking accelerated approval. This is a regulatory milestone. FDA acceptance and PDUFA date were not yet disclosed in the excerpt.

8-KMaterial agreementJun 248-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

uniQure N.V. entered an underwriting agreement on June 23, 2026 for a public offering of 4,945,055 ordinary shares at $45.50/share. The underwriter greenshoe option (741,758 additional shares) was exercised in full on June 24, 2026. Total net proceeds estimated at ~$242.7M after underwriting discounts and expenses. Material — confirms the capital raise details; proceeds fund gene therapy pipeline and potential commercialization of DT120.

424B5Prospectus supplement (offering)Jun 24424B5
AI summary

uniQure N.V. priced a public offering of 4,945,055 ordinary shares at $45.50 per share on June 23, 2026, raising ~$225M gross (~$211.5M net), with underwriters led by Leerink Partners. The greenshoe option of 741,758 additional shares was exercised in full on June 24, 2026, bringing total net proceeds to ~$242.7M. Material dilution event at a discount to the prior day's close of $49.04; proceeds will fund gene therapy R&D and potential DT120 commercialization preparation.

424B5Prospectus supplement (offering)Jun 22424B5
AI summary

QURE filed a 424B5 prospectus supplement on 2026-06-22 of 150,000,000 Ordinary Shares at $44.39 per share. This represents dilution happening now.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

The Netherlands ​ ​ ​ 001-36294 ​ ​ ​ N/A disclosed: pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ Item 7.01 Regulation FD Disclosure. On June 19, 2026, uniQure N.V. (the “ Company ”) issued a press release announcing preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. ​ The information provided in th.

8-KOfficer or director changeJun 158-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

uniQure N.V. filed an 8-K (Items 5.02, 5.03, 5.07) dated June 10, 2026, reporting officer/director changes, an amendment to articles of incorporation or bylaws, and shareholder vote results from its annual meeting. The excerpt is cover-page only with no specifics on which directors/officers changed or what bylaw amendment was approved. The combination of governance changes and a charter amendment may reflect board refreshment or structural changes relevant to uniQure's clinical-stage gene therapy programs.

8-KPress release / Reg FDApr 308-K — Item 7.01: Press release / Reg FD
AI summary

uniQure N.V. filed an 8-K under Item 7.01 (Reg FD) on April 30, 2026, furnishing an investor presentation for this Netherlands-based gene therapy company. The excerpt is XBRL boilerplate with no topic or slide content visible. Routine Reg FD disclosure — for a clinical-stage biotech like uniQure, investor presentations often include pipeline updates and clinical data readouts, making the attached exhibit potentially relevant for AMT-130 (Huntington's) development timeline watchers.

+ 17 other (8 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

uniQure: The Market Graded The Wrong Examseekingalpha.com·1d agouniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investmentsnewsfilecorp.com·3d agouniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Reviewdefenseworld.net·8d agoCedar Grove Capital Q3 2026 Portfolio Updateseekingalpha.com·9d agoUNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Dropbusinesswire.com·10d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport